{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:30:47Z","timestamp":1785281447588,"version":"3.55.0"},"reference-count":320,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bmc.2021.116340","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T01:41:08Z","timestamp":1628473268000},"page":"116340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications"],"prefix":"10.1016","volume":"46","author":[{"given":"Thais","family":"Cristina Mendon\u00e7a Nogueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Vinicius Nora de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116340_b0005","unstructured":"U.S. Food and Drug Administration (FDA). Novel Drug Approvals for 2020. https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2020; 2020 Accessed 20 November 2020."},{"issue":"1\u20133","key":"10.1016\/j.bmc.2021.116340_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2021.116340_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-2272-7_3","article-title":"Getting across the cell membrane: an overview for small molecules, peptides, and proteins","volume":"1266","author":"Yang","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b0025","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bmc.2021.116340_b0035","unstructured":"Blueprint Medicines. Blueprint Medicines Announces FDA Approval of GAVRETO\u2122 (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer. https:\/\/www.prnewswire.com\/news-releases\/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adults-with-metastatic-ret-fusion-positive-non-small-cell-lung-cancer-301124707.html; 2020 Accessed 20 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0040","unstructured":"Blueprint Medicines Corporation. GAVRETO\u2122 (pralsetinib): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213721s000lbl.pdf; 2020 Accessed 07 July 2021."},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-Art Strategies for Targeting RET-Dependent Cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in Targeting RET-Dependent Cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101063","article-title":"The current landscape of the FDA approved companion diagnostics","volume":"14","author":"J\u00f8rgensen","year":"2021","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b0065","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged nonsmall-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00386","article-title":"Immunophenotype and response to immunotherapy of RETrearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"48","key":"10.1016\/j.bmc.2021.116340_b0075","first-page":"1","article-title":"New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)","volume":"22","author":"Russo","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bmc.2021.116340_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/803171","article-title":"Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma","volume":"2013","author":"Giunti","year":"2013","journal-title":"Int J Endocrinol"},{"issue":"27","key":"10.1016\/j.bmc.2021.116340_b0085","first-page":"1","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"15_suppl.","key":"10.1016\/j.bmc.2021.116340_b0090","article-title":"Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b0095","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.bmc.2021.116340_b0100","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RETrearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bmc.2021.116340_b0110","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusionpositive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728222.2013.758715","article-title":"RET inhibition: implications in cancer therapy","volume":"17","author":"Borrello","year":"2013","journal-title":"Expert Opin Ther Targets"},{"issue":"15","key":"10.1016\/j.bmc.2021.116340_b0120","article-title":"Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers","volume":"37","author":"Taylor","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0125","first-page":"472","article-title":"RET kinase alterations in targeted cancer therapy","volume":"3","author":"Liu","year":"2020","journal-title":"Cancer Drug Resist"},{"issue":"14 Suppl","key":"10.1016\/j.bmc.2021.116340_b0130","article-title":"Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors [abstract]","volume":"76","author":"Rahal","year":"2016","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b0135","doi-asserted-by":"crossref","first-page":"S701","DOI":"10.1016\/j.jtho.2019.08.1491","article-title":"P2.03-44 BLU-667 demonstrates robust activity in RET fusion-driven intracranial tumor models","volume":"14","author":"Evans","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b0140","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920928634","article-title":"Current management of RET rearranged non-small cell lung cancer","volume":"12","author":"Stinchcombe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0150","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/S0959-8049(16)33028-3","article-title":"The development of a potent, KDR\/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers","volume":"69","author":"Brandhuber","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b0155","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-therapy-patients-lung-and-thyroid-cancers-certain-genetic-mutation-or-fusion; 2020 Accessed 20 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0160","unstructured":"U.S. Food and Drug Administration (FDA). Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/fast-track-breakthrough-therapy-accelerated-approval-priority-review; 2020 Accessed 20 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0165","article-title":"FDA approves first RET inhibitor","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bmc.2021.116340_b0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET- driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.bmc.2021.116340_b0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.102","article-title":"A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers","volume":"36","author":"Drilon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0180","unstructured":"Drilon A, Oxnard GR, Wirth L, et al. PL02.08 Registrational results of LIBRETTO-001: A phase 1\/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. Presented at: IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract PL02.08. https:\/\/www.loxooncology.com\/docs\/presentations\/LOXO-292-Registrational-Results-LIBRETTO-001_v2.pdf; 2019 Accessed 20 November 2020."},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b0185","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jtho.2019.08.059","article-title":"PL02.08: registrational results of LIBRETTO-001: a Phase 1\/2 Trial of LOXO-292 in patients with RET fusion-positive lung cancers","volume":"14","author":"Drilon","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"suppl 5; abstr","key":"10.1016\/j.bmc.2021.116340_b0190","doi-asserted-by":"crossref","first-page":"v933","DOI":"10.1093\/annonc\/mdz394.093","article-title":"LBA93 - Registrational results of LOXO-292 in patients with RET-altered thyroid cancers","volume":"30","author":"Wirth","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0195","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcp.10252","article-title":"RET and NTRK1 proto-oncogenes in human diseases","volume":"195","author":"Alberti","year":"2003","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b0205","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b0210","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0215","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"1","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.bmc.2021.116340_b0220","unstructured":"Astrazeneca. Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know. https:\/\/www.astrazeneca-us.com\/media\/astrazeneca-us-blog\/2018\/clinical-trial-endpoints-in-cancer-research-four-terms-you-should-know-09242018.html#; 2018 Accessed 13 July 2021."},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0225","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res"},{"issue":"suppl; abstr","key":"10.1016\/j.bmc.2021.116340_b0230","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1200\/jco.2013.31.15_suppl.8067","article-title":"Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials","volume":"31","author":"Drilon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0235","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0240","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.07.009","article-title":"Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma","volume":"82","author":"Go","year":"2013","journal-title":"Lung Cancer"},{"issue":"15_suppl.","key":"10.1016\/j.bmc.2021.116340_b0245","article-title":"RET rearrangements detected by FISH in \u201cpan-negative\u201d lung adenocarcinoma","volume":"31","author":"Varella-Garcia","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0250","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1476-4598-13-176","article-title":"KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer","volume":"13","author":"Qian","year":"2014","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0255","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non- small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer","volume":"13","author":"Ferrara","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: a bridge between 27. cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2021.116340_b0270","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0275","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","article-title":"New paradigms in anticancer therapy: targeting multiple signaling path- ways with kinase inhibitors","volume":"33","author":"Faivre","year":"2006","journal-title":"Semin Oncol"},{"issue":"24","key":"10.1016\/j.bmc.2021.116340_b0280","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1158\/1078-0432.CCR-09-0786","article-title":"Targeting RET receptor tyrosine kinase activation in cancer","volume":"16","author":"Phay","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0285","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pneurobio.2012.06.002","article-title":"TrkB inhibition as a therapeutic target for CNS-related disorders","volume":"98","author":"Boulle","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmc.2021.116340_b0290","first-page":"1","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1(2), e000023","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.bmc.2021.116340_b0295","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer 2020 Accessed 20 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0300","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer; 2020 Accessed 20 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0305","unstructured":"Novartis. TABRECTATM (capmatinib): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf; 2020 Accessed 20 November 2020."},{"issue":"22","key":"10.1016\/j.bmc.2021.116340_b0310","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b0315","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-18-2814","article-title":"Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with De ned Mechanisms of MET Activation","volume":"25","author":"Baltschukat","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2021.116340_b0320","unstructured":"Foundation Medicine. Foundation Medicine Receives FDA Approval for FoundationOne\u00aeCDx as the Companion Diagnostic for Tabrecta\u2122 (capmatinib), the Only FDA-Approved MET Inhibitor for Patients With Metastatic Non-Small Cell Lung Cancer With METex14. https:\/\/www.foundationmedicine.com\/press-releases\/0f19426e-6c6b-4d75-8801-789b6f603eb2; 2020 Accessed 25 March 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0325","unstructured":"Novartis. Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials. https:\/\/www.novartis.com\/news\/media-releases\/novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials; 2019 Accessed 10 March 2021."},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b0330","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.bmc.2021.116340_b0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9509","article-title":"Capmatinib in patients with high-level MET-amplified advanced non\u2013small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study","volume":"38","author":"Wolf","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0340","unstructured":"Novartis. Novartis announces FDA approval of MET inhibitor Tabrecta\u2122 for metastatic non-small cell lung cancer with METex14. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-fda-approval-met-inhibitor-tabrecta-metastatic-non-small-cell-lung-cancer-metex14; 2020 Accessed 10 March 2021."},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0350","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcb.10358","article-title":"HGF\/SF-met signaling in the control of branching morphogenesis and invasion","volume":"88","author":"Zhang","year":"2003","journal-title":"J Cell Biochem"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0355","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0962-8924(03)00104-1","article-title":"How to make tubes: Signaling by the Met receptor tyrosine kinase","volume":"13","author":"Rosario","year":"2003","journal-title":"Trends Cell Biol"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0360","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.molmed.2005.04.005","article-title":"Cancer therapy: Can the challenge be MET?","volume":"11","author":"Corso","year":"2005","journal-title":"Trends Mol Med"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b0365","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: A MET-driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0370","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1073\/pnas.0509040103","article-title":"Structural basis of hepatocyte growth factor\/scatter factor and MET signalling","volume":"103","author":"Gherardi","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 1","key":"10.1016\/j.bmc.2021.116340_b0375","first-page":"13","article-title":"c-Met as a target for personalized therapy","volume":"7","author":"Garajova","year":"2015","journal-title":"Transl Oncogenom"},{"issue":"1 Suppl","key":"10.1016\/j.bmc.2021.116340_b0380","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b0385","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-12-2791","article-title":"Targeting the HGF\/c-MET Pathway in Hepatocellular Carcinoma","volume":"19","author":"Goyal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0390","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4143\/crt.2018.052","article-title":"Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib","volume":"51","author":"Kim","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-185","article-title":"Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma","volume":"13","author":"Imura","year":"2014","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b0405","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/cas.13092","article-title":"Functional and therapeutic relevance of hepatocyte growth factor\/c-MET signaling in synovial sarcoma","volume":"107","author":"Imura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmc.2021.116340_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1064-9","article-title":"Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model","volume":"15","author":"Brandes","year":"2015","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0415","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/0008-5472.CAN-15-2581","article-title":"EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating muta- tions in the EGF receptor","volume":"76","author":"Jia","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0420","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/j.jtho.2016.09.018","article-title":"D-W.; MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC.Topic: Medical Oncology","volume":"11","author":"Bauer","year":"2016","journal-title":"J Thorac Onc"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0425","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","article-title":"Personalized preclinical trials in BRAF inhibitor-resistant patient- derived xenograft models identify second-line combination therapies","volume":"22","author":"Krepler","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0430","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/1878-0261.12039","article-title":"Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells","volume":"11","author":"Han","year":"2017","journal-title":"Mol Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0435","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cllc.2016.11.006","article-title":"Preclinical evaluation of MET inhibitor INC-280 with and without the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung cancer","volume":"18","author":"Lara","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919889001","article-title":"A phase II study of the e cacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma","volume":"11","author":"Qin","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0445","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-fourth-line-treatment-advanced-gastrointestinal-stromal-tumors; 2020 Accessed 20 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0450","unstructured":"American Cancer Society (ACS). Targeted Drug Therapy for Gastrointestinal Stromal Tumors. https:\/\/www.cancer.org\/cancer\/gastrointestinal-stromal-tumor\/treating\/targeted-therapy.html; 2020 Accessed 25 November 2020."},{"issue":"Suppl_8","key":"10.1016\/j.bmc.2021.116340_b0455","article-title":"Initial results of phase 1 study of DCC-2618, a broad-spectrum KIT and PDGFRA inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens","volume":"29","author":"George","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0460","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumor (GIST): a randomized, double-blind, placebo-controlled phase 3 study (INVICTUS)","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0465","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1055-9965.EPI-14-1002","article-title":"Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study","volume":"24","author":"Ma","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11864-015-0384-y","article-title":"The role of surgery in metastatic gastrointestinal stromal tumors","volume":"17","author":"Keung","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0475","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.2217\/fon-2019-0633","article-title":"Intrigue: phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib","volume":"16","author":"Nemunaitis","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0480","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2017.74.9705","article-title":"Gastrointestinal Stromal Tumors","volume":"36","author":"von Mehren","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0485","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/fon-2016-0192","article-title":"Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications","volume":"13","author":"Szucs","year":"2017","journal-title":"Future Oncol"},{"issue":"22","key":"10.1016\/j.bmc.2021.116340_b0490","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.bmc.2021.116340_b0495","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0500","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.pathmechdis.3.121806.151538","article-title":"Molecular pathobiology of gastrointest- inal stromal sarcomas","volume":"3","author":"Corless","year":"2008","journal-title":"Annu Rev Pathol-Mech"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b0505","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"issue":"15 Supplement","key":"10.1016\/j.bmc.2021.116340_b0510","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1158\/1538-7445.AM2015-2690","article-title":"Abstract 2090: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models","volume":"75","author":"Smith","year":"2015","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.bmc.2021.116340_b0515","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OTT.S241331","article-title":"The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor","volume":"2020","author":"Liu","year":"2020","journal-title":"OncoTargets Ther"},{"issue":"414","key":"10.1016\/j.bmc.2021.116340_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2021.116340_b0525","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2018.06.016","article-title":"Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases","volume":"191","author":"Klug","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2021.116340_b0530","unstructured":"BluePrint. Blueprint Medicines. Blueprint Medicines announces FDA approval of AYVAKITTM (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor. https:\/\/ir.blueprintmedicines.com\/news-releases\/news-release-details\/blueprint-medicines-announces-fda-approval-ayvakittm-avapritinib; 2020 Accessed 30 March 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0535","unstructured":"BluePrint. Blueprint Medicines Corporation. Ayvakit (avapritinib): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212608s000lbl.pdf; 2020 Accessed 30 March 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0540","unstructured":"US Food and Drug Administration (FDA). FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. https:\/\/www.fda.gov\/news-events\/press-announc-ements\/fda-approves-first-targeted-therapy-treat-rare-mutation-patients-gastrointestinal-stromal-tumors; 2020 Accessed 30 March 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0545","unstructured":"U.S. SEC United States Securities and Exchange Commission. Form 8-K. http:\/\/ir.blueprintmedicines.com\/static-files\/760ac82a-c1ad-4d52-bcba-b3bd3bdb6310; 2020 Accessed 30 March 2021."},{"issue":"Suppl_15","key":"10.1016\/j.bmc.2021.116340_b0550","article-title":"Clinical activity of avapritinib in\u2265 fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST)","volume":"37","author":"Heinrich","year":"2019","journal-title":"J Clin Oncol Conf"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0555","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0560","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","article-title":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Longterm efficacy and safety data from the NAVIGATOR phase I trial","volume":"145","author":"Jones","year":"2021","journal-title":"Eur J Can"},{"key":"10.1016\/j.bmc.2021.116340_b0565","doi-asserted-by":"crossref","unstructured":"Heinrich M, Jones R, Mehren VM. Clinical response to avapritinib by RECIST and Choi Criteria in \u22654th Line and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST) (oral presentation). In: Connective Tissue Oncology Society annual meeting. https:\/\/www.blueprintmedicines.com\/wp-content\/uploads\/2019\/11\/Blueprint-Medicines-CTOS-2019-Avapritinib-GIST-Clinical-Response-RECIST-Choi-Criteria-Presentation.pdf; 2019 Accessed 20 April 2021.","DOI":"10.1200\/JCO.2019.37.15_suppl.11022"},{"key":"10.1016\/j.bmc.2021.116340_b0570","unstructured":"BluePrint. Blueprint Medicines Corporation. Blueprint Medicines Announces European Commission Approval of AYVAKYT\u00ae (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors. https:\/\/www.prnewswire.com\/news-releases\/blueprint-medicines-announces-european-commission-approval-of-ayvakyt-avapritinib-for-the-treatment-of-adults-with-unresectable-or-metastatic-pdgfra-d842v-mutant-gastrointestinal-stromal-tumors-301138281.html; 2020 Accessed 04 May 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0575","first-page":"1","article-title":"Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing","volume":"6(8), e20294","author":"Ducimeti\u00e8re","year":"2011","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.bmc.2021.116340_b0580","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"Casali","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl_8","key":"10.1016\/j.bmc.2021.116340_b0585","article-title":"Voyager: an open-label, randomized, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)","volume":"29","author":"Bauer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0590","unstructured":"BluePrint. Blueprint Medicines Corporation. Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor. https:\/\/ir.blueprintmedicines.com\/news-releases\/news-release-details\/blueprint-medicines-announces-top-line-results-phase-3-voyager; 2020 Accessed 30 January 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0595","unstructured":"BluePrint. Blueprint Medicines Corporation. Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership. http:\/\/ir.blueprintmedicines.com\/news-releases\/news-release-details\/blueprint-medicines-reports-portfolio-milestones-and-outlines; 2021 Accessed 15 March 2021."},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0600","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.18203\/2319-2003.ijbcp20202960","article-title":"Avapritinib: novel hope for patients with metastatic gist with PDGFRA exon 18 mutation","volume":"9","author":"Maggo","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0605","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0610","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b0615","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/hupa.2002.124122","article-title":"Clinical management of gastrointestinal stromal tumors: before and after STI571","volume":"33","author":"Dematteo","year":"2002","journal-title":"Hum Pathol"},{"issue":"16","key":"10.1016\/j.bmc.2021.116340_b0620","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"European Organisation for Research and Treatment of Cancer. Outcome of patients with plateletderived growth factor receptor alphamutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0625","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4143\/crt.2015.015","article-title":"Efficacy of imatinib in patients with plateletderived growth factor receptor alphamutated gastrointestinal stromal tumors","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0630","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/ijms19030732","article-title":"Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene","volume":"19","author":"Indio","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0635","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2021.116340_b0640","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Soft Tissue Sarcoma, version 2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf; 2020 Accessed 02 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0645","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts; 2020 Accessed 24 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0650","first-page":"1","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15(4), e0231877","author":"Liu","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2021.116340_b0655","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion; 2020 Accessed 26 November 2020."},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b0660","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920937889","article-title":"A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal\u2013gastric junction\/gastric cancer trastuzumab resistant: the FiGhTeR trial","volume":"12","author":"Merz","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0670","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0675","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b0680","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2021.116340_b0685","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0690","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0695","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pharmthera.2009.10.001","article-title":"De-regulated FGF receptors as therapeutic targets in cancer","volume":"125","author":"Knights","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0700","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2021.116340_b0705","first-page":"1","article-title":"Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications","volume":"9(12), e115383","author":"Churi","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0710","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0715","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-14-1432","article-title":"Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer","volume":"5","author":"Dienstmann","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2021.116340_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0725","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cells9030688","article-title":"New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells"},{"issue":"151","key":"10.1016\/j.bmc.2021.116340_b0730","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"2020","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2021.116340_b0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919833519","article-title":"HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance","volume":"11","author":"Pernas","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"10.1016\/j.bmc.2021.116340_b0740","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-Targeted Therapies for HER2-Positive Metastatic Breast Cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b0745","unstructured":"Seattle Genetics. Seattle Genetics announces the approval of TUKYSATM (tucatinib) in Switzerland for the treatment of patients with metastatic HER2-positive breast cancer. https:\/\/www.businesswire.com\/news\/home\/20200512005217\/en; 2020 Accessed 20 November 2020."},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b0750","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","article-title":"Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study","volume":"19","author":"Murthy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0755","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2021.116340_b0760","unstructured":"Broderick, J.M. FDA approves tucatinib for HER2+ breast cancer. OncLive. https:\/\/www.onclive.com\/web-exclusives\/fda-approves-tucatinib-for-her2-breast-cancer; 2020 Accessed 20 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0765","unstructured":"Seattle Genetics. TUKYSA (tucatinib) tablets: US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213411s000lbl.pdf; 2020 Accessed 20 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0770","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-new-drug-under-international-collaboration-treatment-option-patients-her2; 2020 Accessed 27 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0775","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves tucatinib for patients with HER2-positive metastatic breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer; 2020 Accessed 27 November 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0780","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40265-020-01340-w","article-title":"Tucatinib: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"issue":"Suppl_9","key":"10.1016\/j.bmc.2021.116340_b0785","article-title":"Abstract #1795: In vitro and in vivo activity of activity of ARRY-380: a potent, small molecule inhibitor of ErbB2","volume":"69","author":"Pheneger","year":"2009","journal-title":"Cancer Res"},{"issue":"Suppl_9","key":"10.1016\/j.bmc.2021.116340_b0790","article-title":"Abstract #5581: In vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB-2 in combination with trastuzumab or docetaxel in a BT-474 human breast carcinoma xenograft model","volume":"69","author":"Lee","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0795","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/annonc\/mdp373","article-title":"An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer","volume":"21","author":"Capri","year":"2010","journal-title":"Ann Oncol"},{"issue":"8 Supplement","key":"10.1016\/j.bmc.2021.116340_b0800","article-title":"Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice","volume":"72","author":"Dinkel","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b0805","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","article-title":"Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients withhumanepidermalgrowthfactorreceptor 2-positive breast cancer and brain metastases","volume":"34","author":"Freedman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b0810","doi-asserted-by":"crossref","first-page":"djw037","DOI":"10.1093\/jnci\/djw037","article-title":"Lapatinib- related rash and breast cancer outcome in the ALTTO phase III randomized trial","volume":"108","author":"Sonnenblick","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.bmc.2021.116340_b0815","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0820","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-019-1112-5","article-title":"Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial","volume":"21","author":"Mortimer","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0825","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","article-title":"The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea","volume":"175","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0830","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical activity of HER2- selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0835","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jcph.1750","article-title":"Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects","volume":"61","author":"Topletz-Erickson","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b0840","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2\/HER2-positive meta- static breast cancer: a phase 1b clinical trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Suppl_5","key":"10.1016\/j.bmc.2021.116340_b0845","doi-asserted-by":"crossref","first-page":"v200","DOI":"10.1093\/annonc\/mdz246.005","article-title":"527PD - Trastuzumab and tucatinib for the treatment of HER2 amplied metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial","volume":"30","author":"Strickler","year":"2019","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.bmc.2021.116340_b0850","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2016.34.15_suppl.513","article-title":"Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases","volume":"34","author":"Borges","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b0855","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2018.05.004","article-title":"Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer","volume":"67","author":"Duchnowska","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2021.116340_b0860","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12291-019-00863-8","article-title":"Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer","volume":"36","author":"Kaur","year":"2019","journal-title":"Ind J Clin Biochem"},{"key":"10.1016\/j.bmc.2021.116340_b0865","unstructured":"Amirall. Almirall announces FDA approval of Klisyri\u00ae (tirbanibulin), a new innovative topical treatment for actinic keratosis. https:\/\/www.almirall.com\/newsroom\/news\/almirall-announces-fda-approval-of-klisyri\u00ae-tirbanibulin-a-new-innovative-topical-treatment-for-actinic-keratosis; 2020 Accessed 10 December 2020."},{"key":"10.1016\/j.bmc.2021.116340_b0870","unstructured":"Almirall. Almirall U.S. Launches Klisyri\u00ae (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis. https:\/\/www.prnewswire.com\/news-releases\/almirall-us-launches-klisyri-tirbanibulin-a-new-innovative-topical-treatment-for-actinic-keratosis-301230528.html; 2020 Accessed 10 December 2020."},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b0875","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<24::AID-IJC6>3.0.CO;2-1","article-title":"Site distribution of different types of skin cancer: new aetiological clues","volume":"67","author":"Franceschi","year":"1996","journal-title":"Int J Cancer"},{"issue":"1 Pt 2","key":"10.1016\/j.bmc.2021.116340_b0880","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mjd.2000.103342","article-title":"Epidemiology of actinic keratoses and squamous cell carcinoma","volume":"42","author":"Salasche","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0885","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2009.07.026","article-title":"Spreading pigmented actinic keratosis: a review","volume":"63","author":"Uhlenhake","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b0890","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: a comprehensive strategy","volume":"11","author":"Stockfleth","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0895","first-page":"273","article-title":"Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents","volume":"14","author":"Samrao","year":"2013","journal-title":"Am J Dermatol"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0900","first-page":"285","article-title":"Most common dermatologic conditions encountered by dermatologists and nondermatologists","volume":"94","author":"Wilmer","year":"2014","journal-title":"Cutis"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0905","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin and Chemoprevention Trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b0910","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CIA.S31930","article-title":"Optimal treatment of actinic keratoses","volume":"2013","author":"Uhlenhake","year":"2013","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.bmc.2021.116340_b0915","unstructured":"American Academy of Dermatology (AAC). ACTINIC KERATOSIS: DIAGNOSIS AND TREATMENT. https:\/\/www.aad.org\/public\/diseases\/skin-cancer\/actinic-keratosis-treatment; 2021 Accessed 01 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b0920","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.bjc.6605917","article-title":"A phase Ib dose- escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours","volume":"103","author":"van Herpen","year":"2010","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0925","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2\u2013391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0930","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10637-013-9929-8","article-title":"A phase I trial of KX2\u2013391, a novel non-ATP competitive substrate-pocket-directed SRC inhibitor, in patients with advanced malignancies","volume":"31","author":"Naing","year":"2013","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0935","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","article-title":"Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2\u2013391 and KX2\u2013361)","volume":"61","author":"Smolinski","year":"2018","journal-title":"J Med Chem"},{"issue":"48","key":"10.1016\/j.bmc.2021.116340_b0940","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1074\/jbc.RA119.010732","article-title":"Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of -tubulin explains KXO1\u2019s low clinical toxicity","volume":"294","author":"Niu","year":"2019","journal-title":"J Biol Chem"},{"issue":"Suppl_9","key":"10.1016\/j.bmc.2021.116340_b0945","article-title":"KXO1 (KX2\u2013391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo","volume":"68","author":"Yahao","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b0950","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1016\/j.ejmech.2011.07.050","article-title":"Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities","volume":"46","author":"Fallah-Tafti","year":"2011","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0955","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-011-1513-3","article-title":"KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer","volume":"132","author":"Anbalagan","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b0960","first-page":"114","article-title":"Src in cancer: deregulation and consequences for cell behaviour","volume":"1602","author":"Frame","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b0965","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b0970","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0975","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0560.2007.00807.x","article-title":"Activation of Src-family Tyrosine Kinases in hyperproliferative epidermal disorders","volume":"35","author":"Ayli","year":"2008","journal-title":"J Cutan Pathol"},{"issue":"23","key":"10.1016\/j.bmc.2021.116340_b0980","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1158\/1078-0432.CCR-13-1305","article-title":"Targeting Src and tubulin in muci- nous ovarian carcinoma","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b0985","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/1541-7786.MCR-16-0297-T","article-title":"Dual Src kinase\/pretubulin inhibitor, KX-01, sensitizes ER-negative breast cancers to tamoxifen through ER reexpression","volume":"15","author":"Anbalagan","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b0990","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4143\/crt.2016.168","article-title":"Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.bmc.2021.116340_b0995","article-title":"Photoaffinity labeling studies to better define the mechanism of action for Phase II oncology drug KX2-391 [abstract]","author":"Hangauer","year":"2010","journal-title":"In: Proceedings of the 239th ACS National Meeting; 2010 Mar 21\u201325; San Francisco, CA"},{"key":"10.1016\/j.bmc.2021.116340_b1000","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrm2369","article-title":"Tracking the ends: a dynamic protein network controls the of microtubule tips","volume":"9","author":"Akhmanova","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1005","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase \u00bd inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cncr.27790","article-title":"Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma","volume":"119","author":"Patel","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b1015","unstructured":"European Medicines Agency (EMA). Public summary of opinion on orphan designation: selumetinib for the treatment of neurofibromatosis type 1. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2050-public-summary-opinion-orphan-designation-selumetinib-treatment-neurofibromatosis-type-1_en.pdf; 2019 Accessed 26 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1020","unstructured":"AstraZeneca. Q1 2020 results. https:\/\/www.marketscreener.com\/quote\/stock\/ASTRAZENECA-PLC-4000930\/news\/AstraZeneca-nbsp-Q1-2020-results-announcement-30493096\/; 2020 Accessed 26 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1025","unstructured":"AstraZeneca. Selumetinib granted orphan drug designation in the US for adjuvant treatment of differentiated thyroid cancer. https:\/\/www.astrazeneca.se\/media\/pressmeddelanden\/svenska_pressmeddelanden\/2016\/selumetinib-granted-orphan-drug-designation-in-the-us-for-adjuva.html#!; 2016 Accessed 26 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1030","unstructured":"US Food & Drug Administration (FDA). FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas; 2020 Accessed 26 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40272-020-00399-y","article-title":"Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurobromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects","volume":"22","author":"Baldo","year":"2020","journal-title":"Pediatr Drugs"},{"issue":"15","key":"10.1016\/j.bmc.2021.116340_b1040","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neuro bromas in neuro bromatosis type 1: a single-institution experience","volume":"147","author":"Santo","year":"2020","journal-title":"J Neurooncol"},{"issue":"Pt 6","key":"10.1016\/j.bmc.2021.116340_b1050","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","article-title":"Von Recklinghausen neurobromatosis. A clinical and population study in south-east Wales","volume":"111","author":"Huson","year":"1988","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurobromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.bmc.2021.116340_b1065","doi-asserted-by":"crossref","first-page":"i143","DOI":"10.1093\/neuonc\/noy059.515","article-title":"NFM-07. SPRINT: Phase II Study of the MEK 1\/2 Inhibitor Selumetinib (AZD6244, ARRY-142886) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro-oncol"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1070","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2340\/00015555-2975","article-title":"Epidemiological analysis of major complications requiring medical intervention in patients with neurofibromatosis 1","volume":"98","author":"Yoshida","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/1346-8138.15194","article-title":"Distribution of diffuse plexiform neurofibroma on the body surface in patients with neurobromatosis 1","volume":"47","author":"Ehara","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.bmc.2021.116340_b1080","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1\u2013Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b1085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neuro bromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b1090","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","article-title":"Selumetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b1095","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/nsmb859","article-title":"Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition","volume":"11","author":"Ohren","year":"2004","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/13543784.2015.982275","article-title":"Selumetinib for the treatment of cancer","volume":"24","author":"Ciombor","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2021.116340_b1105","unstructured":"US Food & Drug Administration (FDA). Drug Trials Snapshots: TAZVERIK. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-tazverik; 2020 Accessed 26 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1110","unstructured":"US Food & Drug Administration (FDA). FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-option-specifically-patients-epithelioid-sarcoma-rare-soft-tissue; 2020 Accessed 25 April 2021."},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b1115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/21678707.2020.1809377","article-title":"Tazemetostat as a treatment for epithelioid sarcoma","volume":"8","author":"Weiss","year":"2020","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.bmc.2021.116340_b1120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1125","doi-asserted-by":"crossref","first-page":"814","DOI":"10.5858\/133.5.814","article-title":"Epithelioid sarcoma","volume":"133","author":"Armah","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"15_suppl","key":"10.1016\/j.bmc.2021.116340_b1130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.11003","article-title":"Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950)","volume":"37","author":"Stacchiotti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b1135","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Onco"},{"key":"10.1016\/j.bmc.2021.116340_b1140","unstructured":"Ng VY, Conrad EU. Primary (Malignant) Lymphoma of Bone. https:\/\/emedicine.medscape.com\/article\/1256034-overview; 2019 Accessed 03 March 2021."},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b1145","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0840","article-title":"EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL","volume":"16","author":"Brach","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective Inhibition of EZH2 by EPZ- 6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non- Hodgkin Lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b1155","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1160","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.sbi.2003.10.003","article-title":"SET domains and histone methylation","volume":"13","author":"Xiao","year":"2003","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bmc.2021.116340_b1165","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc2736","article-title":"Polycomb group proteins: Navigators of lineage pathways led astray in cancer","volume":"9","author":"Bracken","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1175","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1180","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tig.2014.05.001","article-title":"A rationale to target the SWI\/SNF complex for cancer therapy","volume":"30","author":"Hohmann","year":"2014","journal-title":"Trends Genet"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molcel.2013.10.030","article-title":"Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity","volume":"53","author":"Ferrari","year":"2014","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PAP.0000000000000102","article-title":"Epithelioid Sarcoma: Diagnostic Features and Genetics","volume":"23","author":"Thway","year":"2016","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cas.13173","article-title":"Oncogenic roles of SMARCB1\/INI1 and its deficient tumors","volume":"108","author":"Kohashi","year":"2017","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1200","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b1205","series-title":"Encyclopedia of Cancer","first-page":"1","article-title":"Epigenetic Therapy","volume":"2","author":"Bennett","year":"2019"},{"issue":"Article 986","key":"10.1016\/j.bmc.2021.116340_b1210","first-page":"1","article-title":"Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non- Hodgkin Lymphoma","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.bmc.2021.116340_b1215","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-myelodysplastic-syndromes-mds-can-be-taken-home; 2020 Accessed 20 April 2021."},{"issue":"26","key":"10.1016\/j.bmc.2021.116340_b1220","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1225","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b1230","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000489702","article-title":"Myelodysplastic Syndrome Updated","volume":"86","author":"Hasserjian","year":"2019","journal-title":"Pathobiology"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1240","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b1245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-rissk myelodysplastic syndromes: a randomized, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1250","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","article-title":"Discontinuation of hypomethylating agent therapy in patients with myelodysphastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up","volume":"39","author":"Cabrero","year":"2015","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b1255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/epi.15.66","article-title":"Will next-generation agentes deliver on the promise of epigenetic hypomethylation therapy?","volume":"7","author":"Lowder","year":"2015","journal-title":"Epigenomics"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1260","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in mielodysplastic syndromes: a multicenter, open-label, dose-escalation, phase I study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1265","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine: a phase 2, pharmacokinetic\/pharmacodynamic, randomized, crossover study in MDS and CMML","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bmc.2021.116340_b1270","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2526.2526","article-title":"Preclinical data in cynomolgus (cyn) monkeys of ASTX727, a novel oral hypomethylation agent (HMA) composed of low-dose oroal decitabine combined with a novel cytidine deaminase inhibitor (CDAi) E7727","volume":"122","author":"Oganesian","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1275","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm401856k","article-title":"Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase","volume":"57","author":"Ferraris","year":"2014","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2021.116340_b1280","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2217\/fon-2020-1210","article-title":"Role of cedazuridine\/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"17","author":"Thota","year":"2021","journal-title":"Future Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.bmc.2021.116340_b1285","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2\u2019-deoxycytidine (decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bmc.2021.116340_b1290","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-642-01222-8_10","volume":"184","author":"Daskalakis","year":"2010","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1295","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/14750708.2.6.835","article-title":"Decitabine in myelodysplastic syndromes","volume":"2","author":"Jabbour","year":"2005","journal-title":"Therapy"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1300","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/03602532.2018.1437446","article-title":"Effects of 5-Aza-2\u2032-deoxycytidine (decitabine) on gene expression","volume":"50","author":"Seelan","year":"2018","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1305","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2006.07.010","article-title":"Decitabine\u2014Bedside to bench","volume":"61","author":"Oki","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b1310","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.23463","article-title":"Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2021.116340_b1315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","article-title":"Clinical update on hypomethylating agents","volume":"110","author":"Duchmann","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bmc.2021.116340_b1320","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer; 2020. Accessed 01 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1325","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-020-02513-y","article-title":"Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia","volume":"69","author":"Risnik","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1330","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1335","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1470-2045(20)30097-8","article-title":"New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer","volume":"21","author":"Arrieta","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1340","doi-asserted-by":"crossref","first-page":"1795995","DOI":"10.1080\/2162402X.2020.1795995","article-title":"Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer","volume":"9","author":"Kepp","year":"2020","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1345","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1350","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-11-0252","article-title":"Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells","volume":"10","author":"Soares","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1355","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","article-title":"First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors","volume":"20","author":"Elez","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1360","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10637-017-0427-2","article-title":"Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly x 2 every-3-week schedule","volume":"35","author":"Jimeno","year":"2017","journal-title":"Investig New Drugs"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1365","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdx111","article-title":"Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant\/refractory advanced ovarian cancer","volume":"28","author":"Poveda","year":"2017","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.bmc.2021.116340_b1370","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1200\/JCO.2018.78.6558","article-title":"Multicenter phase II study of lurbi- nectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy","volume":"36","author":"Cruz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1375","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/hon.2557","article-title":"Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"37","author":"Benton","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bmc.2021.116340_b1380","unstructured":"Cancer.gov. Lurbinectedin. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/lurbinectedin; 2021. Accessed 01 April 2021."},{"issue":"18","key":"10.1016\/j.bmc.2021.116340_b1385","doi-asserted-by":"crossref","first-page":"8248","DOI":"10.1093\/nar\/gkr512","article-title":"Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: Insight from molecular dynamics simulations","volume":"39","author":"Bueren-Calabuig","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.bmc.2021.116340_b1390","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/ijc.28213","article-title":"Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104)","volume":"133","author":"Romano","year":"2013","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b1395","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA poly- merase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamar\u00eda Nu\u00f1ez","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"11_Supplement","key":"10.1016\/j.bmc.2021.116340_b1400","doi-asserted-by":"crossref","first-page":"A174","DOI":"10.1158\/1535-7163.TARG-13-A174","article-title":"Abstract A174: Comparison of the antitumor activity of Trabectedin, Lurbinectedin, Zalypsis and PM00128 in a panel of human cells deficient in transcription\/NER repair factors","volume":"12","author":"Moneo","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2021.116340_b1405","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jpba.2016.01.043","article-title":"Development of a liquid chromatography\/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma","volume":"123","author":"Pernice","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b1410","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/fon-2018-0597","article-title":"ATLANTIS: a Phase III study of lurbinectedin\/doxorubicin versus topotecan or cyclophosphamide\/doxorubicin\/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line","volume":"15","author":"Farago","year":"2019","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b1415","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1420","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","article-title":"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells","volume":"70","author":"Germano","year":"2010","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.bmc.2021.116340_b1425","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","article-title":"Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft 37-X of cisplatin-resistant epithelial ovarian cancer","volume":"18","author":"Vidal","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1430","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.bmc.2021.116340_b1435","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2217\/imt-2017-0046","article-title":"PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo","volume":"9","author":"Kuroda","year":"2017","journal-title":"Immunotherapy"},{"issue":"22","key":"10.1016\/j.bmc.2021.116340_b1440","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2021.116340_b1445","first-page":"1","article-title":"Preclinical investigations of PM01183 (lurbinectedin) as a single agent or in combination with other anticancer agents for clear cell carcinoma of the ovary","volume":"11(3), e0151050","author":"Takahashi","year":"2016","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1450","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00018-016-2362-3","article-title":"Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?","volume":"74","author":"Zhang","year":"2017","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.bmc.2021.116340_b1455","doi-asserted-by":"crossref","first-page":"E582","DOI":"10.1016\/S1470-2045(18)30737-X","article-title":"Lurbinectedin for BRCA-mutated advanced breast cancer","volume":"19","author":"Gourd","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bmc.2021.116340_b1460","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1465","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/jm020180i","article-title":"Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor","volume":"46","author":"Sasaki","year":"2003","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.bmc.2021.116340_b1470","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm200216q","volume":"54","author":"Miwa","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116340_b1475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","article-title":"Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice","volume":"723","author":"Nakata","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b1480","article-title":"Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer","volume":"32","author":"Kittai","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b1485","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.bmc.2021.116340_b1490","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-019-01105-0","article-title":"Relugolix: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2021.116340_b1495","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl_3","key":"10.1016\/j.bmc.2021.116340_b1500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/humrep\/11.suppl_3.3","article-title":"GnRH agonists and uterine leiomyomas","volume":"11","author":"Broekmans","year":"1996","journal-title":"Hum Reprod"},{"issue":"9295","key":"10.1016\/j.bmc.2021.116340_b1505","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0140-6736(01)06797-6","article-title":"Gonadotropin-releasing-hormone-receptor antagonists","volume":"358","author":"Huirne","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1510","first-page":"445","article-title":"Advanced indications for gonadotropin-releasing hormone (GnRH) analogues in gynecological oncology (review)","volume":"23","author":"Sugiyama","year":"2003","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2021.116340_b1515","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0974-1208.142476","article-title":"Gonadotropin-releasing hormone analogs: Understanding advantages and limitations","volume":"7","author":"Kumar","year":"2014","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.bmc.2021.116340_b1520","doi-asserted-by":"crossref","unstructured":"Gupta P, Mahapatra A, Suman A, Singh RK. (March 9th 2021). Effect of Endocrine Disrupting Chemicals on HPG Axis: A Reproductive Endocrine Homeostasis [Online First], IntechOpen. https:\/\/www.intechopen.com\/online-first\/effect-of-endocrine-disrupting-chemicals-on-hpg-axis-a-reproductive-endocrine-homeostasis; 2021 Accessed 01 April 2021. doi: 10.5772\/intechopen.96330.","DOI":"10.5772\/intechopen.96330"},{"issue":"7","key":"10.1016\/j.bmc.2021.116340_b1525","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1530","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose\u2013response manner: a randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga","year":"2021","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bmc.2021.116340_b1535","doi-asserted-by":"crossref","first-page":"529","DOI":"10.12688\/f1000research.14817.1","article-title":"Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment","volume":"8","author":"Rolla","year":"2019","journal-title":"F1000 Faculty Rev"},{"issue":"1","key":"10.1016\/j.bmc.2021.116340_b1540","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2021.116340_b1545","unstructured":"Takeda. Uterine fibroids treatment agent (GnRH antagonists) Rerumina for manufacturing and marketing approval in Japan of Tablets 40 mg. https:\/\/www.takeda.com\/jp\/newsroom\/newsreleases\/2019\/20190108-8038\/; 2019 Accessed 03 January 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1550","unstructured":"Myovant Sciences. ORGOVYX (relugolix): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214621s000lbl.pdf; 2020 Accessed 01 April 2021."},{"issue":"8","key":"10.1016\/j.bmc.2021.116340_b1555","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1358\/dot.2019.55.8.3020179","article-title":"Relugolix for the treatment of uterine fibroids","volume":"55","author":"Barra","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"12","key":"10.1016\/j.bmc.2021.116340_b1560","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bmc.2021.116340_b1565","unstructured":"U.S. Food and Drug Administration (FDA). FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer; 2020 Accessed 02 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1570","unstructured":"U.S. Food and Drug Administration (FDA). Drug Trial Snapshot: ORGOVYX. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-orgovyx; 2020 Accessed 02 April 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1575","unstructured":"Silberstein J. 2020 Top Stories in Advanced Prostate Cancer: Relugolix for Androgen-Deprivation Therapy. Advanced Prostate Cancer. https:\/\/www.practiceupdate.com\/content\/2020-top-stories-in-advanced-prostate-cancer-relugolix-for-androgen-deprivation-therapy\/110656; 2020 Accessed 26 April 2021."},{"issue":"2","key":"10.1016\/j.bmc.2021.116340_b1580","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.bmc.2021.116340_b1585","unstructured":"Cancer.gov. Cancer Statistics. https:\/\/www.cancer.gov\/about-cancer\/understanding\/statistics; 2020 Accessed 16 July 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1590","unstructured":"U.S. Food and Drug Administration (FDA). New Drug Therapy Approvals 2020- Advancing Health Through Innovation. https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/new-drug-therapy-approvals-2020#first-in-class; 2021 Accessed 16 July 2021."},{"key":"10.1016\/j.bmc.2021.116340_b1595","unstructured":"U.S. Food and Drug Administration (FDA). Accelerated Approval. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval; 2018. Accessed 16 July 2021."},{"issue":"5","key":"10.1016\/j.bmc.2021.116340_b1600","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A Decade of FDA-Approved Drugs (2010\u20132019): Trends and Future Directions","volume":"64","author":"Brown","year":"2021","journal-title":"J Med Chem"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621003485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621003485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:15:48Z","timestamp":1760836548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621003485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":320,"alternative-id":["S0968089621003485"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116340","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116340"}}